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Key Points: 
 
 Healthcare workers and students are at increased risk of occupational DR-TB disease 
 HCWs suffer high DR-TB associated morbidity and mortality  
 Innovation, destigmatisation and better TB Infection Control implementation are key to reducing 
DR-TB transmission to HCWs and patients 
 
Words:  38 (limit 40) 
 
 
Abstract: 
 
“Occupational MDR-TB”… "XDR-TB”… “Treatment-induced hearing loss”: three life-changing messages 
imparted over the phone. Three personal accounts are shared to highlight how many healthcare workers 
(HCWs) and students in low-resource settings falsely believe they are immune to tuberculosis (TB) despite 
high levels of exposure. This misconception reflects a lack of awareness of TB transmission and disease risk, 
compounded by the absence of accurate occupational TB estimates. As the global problem of drug-
resistant TB (DR-TB) evolves, HCWs are increasingly infected and suffer considerable morbidity and 
mortality from occupational DR-TB disease. Similarly, healthcare students are emerging as a vulnerable and 
unprotected group. There is an urgent need for improved detection, preventive therapy, enhanced 
treatment and support for affected HCWs and those they care for as well as destigmatisation of all forms of 
TB. Finally, efforts to protect HCWs and prevent DR-TB transmission by universal implementation of TB 
Infection Control measures should be prioritized. 
 
Words: 150 (limit 150) 
 
Main piece - Total words: 2953 (limit 3000) 
 
Introduction: From being a healthcare worker to becoming a patient 
 
The continued and ominous global spread of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-
resistant TB (XDR-TB) poses a major threat to global TB control and global health security. [1] The WHO 
estimates that 480 000 cases were due to MDR-TB in 2013 with increasing prevalence being seen in Eastern 
Europe, Asia and Southern Africa. As many as 9% of these cases could have XDR-TB. [1] In South Africa, drug-
resistant tuberculosis (DR-TB) consumes a third of the total national budget for tuberculosis, [2] with dismal 
cure rates despite admirable political and public health commitment: under 50% for MDR-TB and as low as 
11% for XDR-TB. [3] DR-TB imposes devastating human suffering and isolation; not only upon patients and 
their communities, but also upon those called to care for them. 
 
We share three personal accounts of occupational DR-TB to highlight how healthcare workers (HCWs) and 
students in low-resource settings falsely believe they are immune to tuberculosis (TB) despite high levels of 
exposure, and illustrate how developing DR-TB changed their perspectives on the dire need for better DR-TB 
prevention, treatment and de-stigmatisation. 
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Case history 1: The innocuous beep of the text message heralded the South African doctor’s worst fear: “Bad 
news, high-frequency hearing loss.” The sender, his wife and also a doctor, was sick with MDR-TB. After eight 
weeks of meticulously monitored MDR-TB therapy, she had begun losing her hearing. Alarm bells ring - will 
this progress to total deafness and also loss of her career? He was sick too, in bed during the past week with 
presumed primary pleural MDR-TB.  
 
Case history 2: Fast forward a year and a half, a phone rings with similar news to that of the medical couple: 
“You need to go back to the clinic…you have MDR-TB.” This time the message was delivered by a seemingly 
indifferent laboratory technician to a profoundly isolated and confused medical student. Her worst fear had 
been that the presumed drug-sensitive TB might have resulted in missing time from her studies. Now she 
worried for her life; a few years previously another student at her Medical School had tragically lost her battle 
with MDR-TB. 
 
Case history 3: Fast forward another year and another doctor’s phone rings with the message: “You have 
XDR-TB.” Just like that, in the middle of a shopping mall, delivered by another laboratory technician with a 
pressing schedule – there were many more results to phone out.  
 
Whilst the risk of contracting of TB in health care settings is well described, these young HCWs never expected 
that it would happen to them, let alone primary MDR/XDR-TB. They all shared the same profession, but were 
previously healthy and lacked the ‘typical’ risk factors for developing active TB disease. They all held the 
falsely reassuring belief that ‘healthy’ HCWs are unlikely to contract TB and that they were in fact ‘TB Proof’ 
(immune to developing TB disease). Another such false belief, that DR-TB is largely ‘acquired’ due to 
inadequate or interrupted treatment, has also been increasingly dispelled, with a systematic global review 
finding that up to three quarters of DR-TB cases were due to primary transmission (i.e. person to person 
spread, frequently in treatment naïve individuals). [4] 
 
A threat to life and career 
 
The harsh and largely unacknowledged reality is that globally HCWs are three times more likely to contract 
TB than the general population, [5] and in South Africa, are up to six times more likely to contract DR-TB. [6] 
The unexpected news of having been diagnosed with DR-TB can be devastating to HCWs who have full 
knowledge of the vexed problems associated with treatment: 1) The high mortality rate: up to a third of 
HCWs diagnosed with DR-TB may die [7,8]  
2) The excess host inflammatory response which leads to permanent damage and long term functional 
disability. [9] 3) Coping with the lengthy treatment duration (of at least 20 months or more) with toxic drugs 
and (frequently irreversible) side-effects. Survivors often battle severe physical and psycho-social side-
effects, [10] some of them career-ending like hearing loss, loss of vision and nerve damage among others. 
[11,12]  
 
The husband got up and spent the next two hours on the phone. With the threat and implications of 
permanent hearing loss foremost in mind, they agonised over whether to stop the offending 
aminoglycoside drug or to continue the ototoxic therapy to have a better chance of cure. “Your life or your 
hearing?” What a terrible ‘choice’ to offer anybody, especially a colleague. A unique third choice, an 
application for compassionate use of the first new TB drug in more than 40 years to replace the 
aminoglycoside, had just been declined too.  
 
The torment experienced during DR-TB therapy at the hands of outdated, ineffective TB ‘treatment’ has 
been well described. [13,14] Less well known is the sense of helplessness and even futility experienced by 
those battling a deadly disease that defies global attempts at control. Of the nearly half a million new MDR-
TB cases in 2013, only 136 412 were diagnosed and even fewer (97 000) were started on appropriate 
therapy. Only about half of these individuals achieved treatment success - less than a tenth of all cases. The 
detection, management and outcomes for XDR-TB are even more dismal with only 7.5% enrolled on 
treatment (3 232 out of an estimated 43200 cases). The latest reported global cure rate was 22%. [1] 
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HCWs are a scarce resource in all countries of the world. Unfortunately many are lost or disabled by 
occupational TB disease in countries where they are needed most. This has a devastating effect on their 
families, colleagues and the patients they serve. A recent study from South Africa that screened 505 HCWs 
for latent TB infection (LTBI) at baseline and a year later found that the annual rate of LTBI was 38% using 
TST (Tuberculin Skin Testing), much higher than previously thought. [15] The situation for HCWs co-infected 
with HIV is even worse; they are often dead long before their DR-TB is even diagnosed. [16] 
 
No DR-TB prophylaxis 
 
The husband’s disease was never conclusively diagnosed. The timing of symptoms and spike in interferon-
gamma release assays (IGRAs) suggested primary transmission from his wife, but in the absence of any 
conclusive diagnostic results, and in the presence of very real and irreversible side-effects, he opted for an 
unconventional and rather ‘un-medical’ choice: doing nothing. His symptoms resolved after three weeks, 
but his IGRAs have remained doggedly inconclusive, fluctuating across the cut-off range, very much in 
keeping with the diagnostic uncertainty described in the latest literature. [17] And scarring in both his lung 
apices, frequently seen during routine screening of HCWs in high burden countries, attest to unrecognised 
encounters with TB. 
 
The WHO cannot currently give any recommendation on preventive therapy for DR-TB contacts, because of 
a glaring lack of research and evidence in this field. [18] This poses a great challenge for families, friends 
and colleagues of HCWs that are diagnosed with this life-threatening disease. And even more so for the 
patients they serve: the wife had been working with neonates for six weeks before her mild, yet persistent 
cough was finally diagnosed as MDR-TB. There was no way of tracing all contacts, and the authorities never 
even tried. 
 
Preventive therapy for children under five years of age is routinely given if a parent or close household 
contact is diagnosed with drug-sensitive TB, as the risk of children developing disease and the related 
morbidity and mortality are high. [19] The doctor diagnosed with XDR-TB was particularly concerned about 
her three year old daughter, but had no proven options for preventive therapy to protect her little one 
from such resistant disease. Every sniffle or cough from her child caused the mother concern for years after 
her diagnosis. 
 
No safety net for students 
 
In South Africa, in keeping with International Labour Organisation (ILO) regulations, [20] TB is classified as 
an occupational disease. This means a HCW who contracts the disease is eligible for compensation 
including medical expenses, income security and reimbursement for temporary or permanent disability and 
death. [21] For medical and other healthcare trainees or students, there is currently no law to enforce 
compensation.   
 
Medical students have been found to have a higher rate of early TST conversion compared to other 
students in a high-burden country setting [22] and a higher prevalence of LTBI during their late clinical 
years, compared to preclinical and early clinical years. [23] A previous review also found a significantly 
higher risk for contracting TB amongst young HCWs compared to older HCWs. [24] Possible contributing 
factors to the high risk among junior HCWs and those in training include a greater amount of time spent 
with patients and decreased awareness of (and even control over) exposure to risk factors compared to 
senior colleagues. [10] Despite these risks, medical and other healthcare students receive no financial 
support for medical expenses, and frequently face discontinuation of their studies and loss of bursaries due 
to disease. The same untenable considerations apply to volunteers, unpaid (or ‘supernumerary’) trainees, 
as well as elective (visiting) students. 
 
5 
 
The medical student with MDR-TB experienced extreme social isolation, driven by a lack of understanding 
from family members, peers, as well as the medical school administrators.   Fortunately she had access to 
free medical treatment through South African public clinics. The daily travel to the clinic to access 
excruciating intra-muscular injections and the progressively more debilitating side-effects soon meant that 
she had to discontinue her studies. She also heard of more students and colleagues who suffered 
permanent side-effects, like hearing loss and nerve damage, and of some who had even lost their lives to 
TB. This elicited intense fear of relapse or re-exposure, especially given the lack of infection control 
measures in the public healthcare facilities where she was training. This anxiety was further compounded 
by severe depression, a common side effect of DR-TB medication. Social isolation, treatment side effects, 
loss of career and stigma all contribute significantly to the high rates of suicide in DR-TB patients. [25,26] 
 
A scarce resource globally 
 
HCWs are in demand in almost every country of the world. Financial incentives and safer working 
conditions are some of the factors that drive migration. [27] Although most HCWs undergo X-ray screening 
before commencing work in a new country, a normal chest X-ray cannot exclude LTBI (or even active 
pulmonary disease in some cases). Some countries offer TSTs or IGRAs, but these cannot reliably estimate 
the risk of progression to active disease. A recent widely publicised case investigation in the United 
Kingdom (UK) tracked nosocomial transmission of MDR-TB from a South African HCW to a hospitalized 
patient, with a delay of disease manifestation in the patient of 49 months. [28] Following TB exposure, the 
risk of disease progression in contacts is highest in the first 2 years, moderate over five years and persists 
lifelong. [29] Predicting who will become sick and when is currently almost impossible. 
 
 
There is currently also no way of determining whether HCWs with LTBI are infected with drug-sensitive (DS) 
or resistant (DR) strains, meaning that  currently available treatment options for DS-LTBI would be 
ineffective for resistant strains at best, and harmful at worst. This uncertainty is compounded for HCWs 
living with HIV, since isoniazid preventive therapy (IPT) is recommended for up to 36 months to both treat 
existing latent infection and prevent new infections in all individuals with HIV in settings with a high TB 
transmission risk. [30] The ability of IPT to protect against transmission of DR-TB strains is not known and 
could inadvertently present a competitive transmission advantage to INH-resistant strains. The WHO 
recently highlighted the need for research to evaluate the risk of selecting for additional drug resistance 
following inappropriate LTBI treatment, stressing the need for studies evaluating efficacy of currently 
recommended treatment options in areas with high prevalence of DR-TB. [18]  
 
HCWs could unwittingly contribute to the global spread of DR-TB, but to stigmatise them due to fear of 
contagion would only worsen the situation. HCWs in low-resource settings with possible TB symptoms are 
already wary of presenting for testing and treatment, because of stigma and career implications. [14] Such 
stigma is amplified for HCWs living with HIV, who are at a 20-50 fold higher risk of developing TB disease. 
[5,16,31] Fear of discrimination prevents disclosure and reduces the likelihood of HCWs accessing support 
and risk modification in the workplace.  
 
Any delay in diagnosis could have catastrophic consequences for the HCW and for the patients that they 
serve. As described in a UK case investigation, three South African HCWs that were co-infected with HIV 
and MDR-TB lost their lives, even though they had treatable conditions. One of the HCWs presented very 
late, in a dire state of health, and authorities subsequently identified more than 500 potentially-infected 
contacts from this single source case. [32] The current lack of latent DR-TB diagnostic and treatment 
choices leave ‘watchful (and lengthy) waiting’ as the only highly unattractive ‘option’. 
 
Novel interventions for improved treatment outcomes 
 
The current status quo of lengthy treatment duration with toxic drugs and poor treatment outcomes 
associated with DR-TB is not acceptable. There is an urgent need, not only for more effective and safer 
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drugs, [13] but also new innovations for shortening the duration of therapy, improving treatment 
outcomes, and repairing and preventing long term lung damage in DR-TB patients. [9] A wide range of Host-
Directed Therapies (HDTs) have now been identified which have the potential to modulate protective 
innate and adaptive immune responses, reduce excess inflammation, repair or prevent tissue damage and 
enhance the effectiveness of DR-TB. [33] These include therapeutic vaccines and the use of the patient’s 
own bone marrow derived stromal cells as adjunct therapy. However, the ultimate priority need is that of 
developing a preventive TB vaccine. 
 
Why a new TB vaccine would make such a difference 
 
It is estimated that a third of the world’s population is infected with TB and an ever increasing number are 
latently infected with drug-resistant strains. There is a renewed sense of urgency to develop a vaccine that 
could prevent disease and halt this age-old pandemic that still ranks as the world’s joint largest infectious 
killer. With a staggering 1.5 million people dying of this disease every year, [1] innovation is essential. 
 
The Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine is the only TB vaccine currently in use. In 
infants it has been shown to reduce disseminated forms of TB, but has limited effectiveness in preventing 
pulmonary TB, especially in older children and adults. [34] Currently there is a shortage of surrogate 
biomarkers to assess the development of protection following vaccination, hampering clinical testing. New 
techniques for more effective vaccine delivery have shown promise, but further research into how the 
immune system responds to infection (initial and latent) and disease is needed to speed up vaccine 
development. [35] 
 
However, to continue the search for vaccine candidates and promote ongoing research into new drug 
development, sustainable investment in research and innovations for TB will be required. [36] A recent 
report from the UK All-Party Parliamentary Group on Global Tuberculosis projected 75 million deaths from 
MDR-TB costing the global economy 16.7 trillion US dollars over the next three decades if we continue the 
status quo. [37]  
 
What should we do today? 
 
A novel vaccine and other new tools to reach the WHO’s ambitious target of TB elimination will clearly not 
be available in the immediate future. [38] As evidence grows of TB transmission in health care facilities, 
both to patients and HCWs, [39,40] the need for full implementation of all recommended TB Infection 
Control (TB-IC) measures in all facilities should be a major focus of prevention efforts. Rigorous 
implementation of TB-IC can achieve reduction in TB transmission to HCWs and to people living with HIV. 
[41,42] In 2009, the WHO produced TB-IC guidelines outlining evidence-based and affordable measures 
(administrative, environmental and personal protective) to reduce the risk of TB transmission within 
hospitals and congregate settings. [43] At a global level a policy guideline for promoting access to care for 
HCWs, specifically focussed on TB and HIV, was published in 2010. [44]  
 
Despite these guidelines and evidence for efficacy, poor implementation of TB-IC in health facilities 
persists. [45] Personal experiences’ of HCWs affected by TB reveal a need for improved educational and 
awareness programmes among all healthcare personnel, including facility managers. Additional suggestions 
of HCWs who survived TB include effective and sustained implementation of TB-IC measures, mandatory 
pre- and post-employment TB screening and a change in attitudes of senior healthcare colleagues and 
administrators. [46] Several studies have also noted that stigmatisation of TB and DR-TB creates a barrier to 
compliance with TB-IC best practice among HCWs who don’t want to seem ‘weak’ or ‘scared’ and therefore 
refrain from wearing N95 respirators. We need to destigmatise TB by breaking down this myth of 
invincibility among HCWs, rooted in an apparent false sense of superior immunity, and through awareness 
campaigns targeting communities most affected by TB. 
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New interventions including an effective vaccine, safe treatment for all forms of latent and active TB, [13] 
active case finding, screening of contacts and increased advocacy for and education about TB-IC at both 
healthcare facility and community levels will accelerate our progress towards TB elimination. [47] And we 
need the political, financial and legislative commitments to effect real change. Without a strong healthcare 
workforce on the front line this battle cannot be won.  
 
From patients to HCW advocates: 
The wife’s hearing and career were saved when her second compassionate use application succeeded. The 
student made a full recovery after missing two years of medical school and the mother has nearly 
completed her arduous two years of XDR-TB treatment. But the vast majority of our colleagues diagnosed 
with DR-TB are not as fortunate. Exposure without protection is simply not an option.  
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